Plaintiffs Filing Zofran Birth Defect Lawsuit Allege Fetal Drug Exposure Caused Death Of Infant Girl

April 06, 2016 – – ZofranLegal.com reports on a lawsuit which was filed by parents from Los Angeles County, California who allege that fetal exposure to anti-nausea drug Zofran while developing in the womb caused their daughter to be born with such severe birth defects, that they resulted in her death. The lawsuit was filed on November 13th, 2015 in a federal court in the Central District of California. The filing parents state that suffering the loss of a child will continue to be, “a pain we carry with us for the rest of our days.” They indicated that they hoped their lawsuit against Zofran manufacturer GlaxoSmithKline would help the cause by working, “to alert other women to the issues with this drug.”

Zofran gained approval from the U.S. Food and Drug Administration (FDA), although, is a point of contention commonly discussed by plaintiffs, the drug was never FDA-approved to treat expectant mothers, or tested for safety on these women and their unborn babies. Instead, the FDA gave approval of Zofran specifically to provide treatment for patients battling episodes of nausea and vomiting after undergoing chemotherapy, radiation therapy, or anesthesia procedures. Despite this specific approval, manufacturer GlaxoSmithKline began to market the drug “off-label” as a safe and effective treatment for women with morning sickness, both to the general public and OB/Gyns across the United States.

Zofran became widely prescribed “off-label” to pregnant women, many of whom claim that they were never made aware that the drug was not FDA approved to treat them. These mothers have filed hundreds of lawsuits against the drug, and similarly allege fetal exposure to the drug through them put their children at increased risk for the development of serious and sometimes fatal birth defects. Defects commonly noted in these lawsuits are cleft lip and palate, atrial and ventricular septal defect, transposition of the greater vessels, respiratory distress, and tetralogy of fallot, to kidney defects, and clubfoot.

Unfortunately, GlaxoSmithKline’s marketing practices have been met with scrutiny before. In 2012, the corporate giant agreed to settle charges filed against them by the U.S. Department of Justice by paying a lump sum. The charges were placed on them by the U.S. DOJ because of their choice to promote multiple prescription drugs “off-label”, one of which was Zofran.

Zofran birth defect lawsuits have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2657 in Boston, Massachusetts. They are currently being overseen by the Honorable Judge F. Dennis Saylor IV. As the legal process progresses and additional lawsuits are filed, the attorneys of Monheit Law are working to ensure that other mothers who have used Zofran while pregnant and who have subsequently given birth to children with defects will be given the important opportunity to fully investigate their legal rights in the matter. Affected women, children, and families may be entitled to significant compensation attained through legal action. To help those deserving, the attorneys of Monheit Law are also currently offering free legal consultations to qualified parties.

To request further information on Zofran lawsuits, or to ask questions, please contact Michael Monheit, Esq., lead attorney of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60009122